Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.

President Trump’s effort to lessen crime in Washington, D.C., and launch a “beautification” effort is clashing with a long tradition of Republicans criticizing and outright writing off the ...